Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study.
The proliferative activity of the tumor cells and the expression of tumor-associated genes and sex steroid hormone receptors were investigated immunohistochemically in ten cases of carcinoma ex pleomorphic adenoma (Ca-ex-PA) of the salivary glands. These were analyzed in benign and malignant components separately, and then were compared with ten cases of the other malignant tumors [adenocarcinomas, not otherwise specified (ACN) and salivary duct carcinomas (SDC)] and ten cases of pleomorphic adenomas (PA). The results obtained in this study were as follows: (1) malignant component of Ca-ex-PA showed a higher incidence of PCNA and Ki67 than benign component of Ca-ex-PA. A significant difference between benign component of Ca-ex-PA and PA was not observed. (2) A significant difference in the incidence of p53, c-erbB-2, EGFR overexpression was observed only between malignant component of Ca-ex-PA and benign component of Ca-ex-PA. (3) The incidence of PCNA, Ki67, p53, c-erbB-2 overexpression in malignant component of Ca-ex-PA showed the highest data among the four groups. These results suggest that Ca-ex-PA acquired the particular biological behavior in contrast to the other salivary neoplasms in the long-standing process while PA undergoes malignant transformation.
Matsubayashi
Saori
S
Department of Otolaryngology, Tokyo Women's Medical University, Tokyo, Japan.
Yoshihara
Toshio
T
D008949:Adenoma, Pleomorphic / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D000368:Aged; D000912:Antibodies, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology* / Q000378:metabolism; D044584:Carcinoma, Ductal / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D003937:Diagnosis, Differential; D066246:ErbB Receptors / Q000276:immunology / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D019394:Ki-67 Antigen / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000276:immunology / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D011944:Receptors, Androgen / Q000276:immunology / Q000378:metabolism; D011960:Receptors, Estrogen / Q000276:immunology / Q000378:metabolism; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology / Q000378:metabolism
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D016159:Tumor Suppressor Protein p53; C512478:EGFR protein, human